Cargando…

Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients

Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for ath...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmelter, Franziska, Föh, Bandik, Mallagaray, Alvaro, Rahmöller, Johann, Ehlers, Marc, Lehrian, Selina, von Kopylow, Vera, Künsting, Inga, Lixenfeld, Anne Sophie, Martin, Emily, Ragab, Mohab, Meyer-Saraei, Roza, Kreutzmann, Fabian, Eitel, Ingo, Taube, Stefan, Käding, Nadja, Jantzen, Eckard, Graf, Tobias, Sina, Christian, Günther, Ulrich L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686182/
https://www.ncbi.nlm.nih.gov/pubmed/34938772
http://dx.doi.org/10.3389/fmolb.2021.737039
_version_ 1784617966513422336
author Schmelter, Franziska
Föh, Bandik
Mallagaray, Alvaro
Rahmöller, Johann
Ehlers, Marc
Lehrian, Selina
von Kopylow, Vera
Künsting, Inga
Lixenfeld, Anne Sophie
Martin, Emily
Ragab, Mohab
Meyer-Saraei, Roza
Kreutzmann, Fabian
Eitel, Ingo
Taube, Stefan
Käding, Nadja
Jantzen, Eckard
Graf, Tobias
Sina, Christian
Günther, Ulrich L.
author_facet Schmelter, Franziska
Föh, Bandik
Mallagaray, Alvaro
Rahmöller, Johann
Ehlers, Marc
Lehrian, Selina
von Kopylow, Vera
Künsting, Inga
Lixenfeld, Anne Sophie
Martin, Emily
Ragab, Mohab
Meyer-Saraei, Roza
Kreutzmann, Fabian
Eitel, Ingo
Taube, Stefan
Käding, Nadja
Jantzen, Eckard
Graf, Tobias
Sina, Christian
Günther, Ulrich L.
author_sort Schmelter, Franziska
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether this is specific for COVID-19 and whether the observed signature is caused by the disease or rather represents an underlying risk factor. To answer this question, we have analyzed 482 serum samples using nuclear magnetic resonance metabolomics, including longitudinally collected samples from 12 COVID-19 and 20 cardiogenic shock intensive care patients, samples from 18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-positive individuals, and single time point samples from 58 healthy controls. COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared with healthy controls. Specifically, very-low-density lipoprotein and intermediate-density lipoprotein particles and associated apolipoprotein B and intermediate-density lipoprotein cholesterol were significantly increased, whereas cholesterol and apolipoprotein A2 were decreased. Moreover, a similarly perturbed profile was apparent when compared with other patients with cardiogenic shock who are in the intensive care unit when looking at a 1-week time course, highlighting close links between COVID-19 and lipid metabolism. The metabolic profile of COVID-19 patients distinguishes those from healthy controls and also from patients with cardiogenic shock. In contrast, anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared with age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized low- and high-density lipoprotein subfractions. Our data suggest that COVID-19 is associated with dyslipidemia, which is not observed in anti-SARS-CoV-2 antibody-positive individuals who have not developed severe courses of the disease. This suggests that lipoprotein profiles may represent a confounding risk factor for COVID-19 with potential for patient stratification.
format Online
Article
Text
id pubmed-8686182
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86861822021-12-21 Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients Schmelter, Franziska Föh, Bandik Mallagaray, Alvaro Rahmöller, Johann Ehlers, Marc Lehrian, Selina von Kopylow, Vera Künsting, Inga Lixenfeld, Anne Sophie Martin, Emily Ragab, Mohab Meyer-Saraei, Roza Kreutzmann, Fabian Eitel, Ingo Taube, Stefan Käding, Nadja Jantzen, Eckard Graf, Tobias Sina, Christian Günther, Ulrich L. Front Mol Biosci Molecular Biosciences Coronavirus disease 2019 (COVID-19) is a viral infection affecting multiple organ systems of great significance for metabolic processes. Thus, there is increasing interest in metabolic and lipoprotein signatures of the disease, and early analyses have demonstrated a metabolic pattern typical for atherosclerotic and hepatic damage in COVID-19 patients. However, it remains unclear whether this is specific for COVID-19 and whether the observed signature is caused by the disease or rather represents an underlying risk factor. To answer this question, we have analyzed 482 serum samples using nuclear magnetic resonance metabolomics, including longitudinally collected samples from 12 COVID-19 and 20 cardiogenic shock intensive care patients, samples from 18 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody-positive individuals, and single time point samples from 58 healthy controls. COVID-19 patients showed a distinct metabolic serum profile, including changes typical for severe dyslipidemia and a deeply altered metabolic status compared with healthy controls. Specifically, very-low-density lipoprotein and intermediate-density lipoprotein particles and associated apolipoprotein B and intermediate-density lipoprotein cholesterol were significantly increased, whereas cholesterol and apolipoprotein A2 were decreased. Moreover, a similarly perturbed profile was apparent when compared with other patients with cardiogenic shock who are in the intensive care unit when looking at a 1-week time course, highlighting close links between COVID-19 and lipid metabolism. The metabolic profile of COVID-19 patients distinguishes those from healthy controls and also from patients with cardiogenic shock. In contrast, anti-SARS-CoV-2 antibody-positive individuals without acute COVID-19 did not show a significantly perturbed metabolic profile compared with age- and sex-matched healthy controls, but SARS-CoV-2 antibody-titers correlated significantly with metabolic parameters, including levels of glycine, ApoA2, and small-sized low- and high-density lipoprotein subfractions. Our data suggest that COVID-19 is associated with dyslipidemia, which is not observed in anti-SARS-CoV-2 antibody-positive individuals who have not developed severe courses of the disease. This suggests that lipoprotein profiles may represent a confounding risk factor for COVID-19 with potential for patient stratification. Frontiers Media S.A. 2021-12-02 /pmc/articles/PMC8686182/ /pubmed/34938772 http://dx.doi.org/10.3389/fmolb.2021.737039 Text en Copyright © 2021 Schmelter, Föh, Mallagaray, Rahmöller, Ehlers, Lehrian, von Kopylow, Künsting, Lixenfeld, Martin, Ragab, Meyer-Saraei, Kreutzmann, Eitel, Taube, Käding, Jantzen, Graf, Sina and Günther. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Molecular Biosciences
Schmelter, Franziska
Föh, Bandik
Mallagaray, Alvaro
Rahmöller, Johann
Ehlers, Marc
Lehrian, Selina
von Kopylow, Vera
Künsting, Inga
Lixenfeld, Anne Sophie
Martin, Emily
Ragab, Mohab
Meyer-Saraei, Roza
Kreutzmann, Fabian
Eitel, Ingo
Taube, Stefan
Käding, Nadja
Jantzen, Eckard
Graf, Tobias
Sina, Christian
Günther, Ulrich L.
Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
title Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
title_full Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
title_fullStr Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
title_full_unstemmed Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
title_short Metabolic and Lipidomic Markers Differentiate COVID-19 From Non-Hospitalized and Other Intensive Care Patients
title_sort metabolic and lipidomic markers differentiate covid-19 from non-hospitalized and other intensive care patients
topic Molecular Biosciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686182/
https://www.ncbi.nlm.nih.gov/pubmed/34938772
http://dx.doi.org/10.3389/fmolb.2021.737039
work_keys_str_mv AT schmelterfranziska metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT fohbandik metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT mallagarayalvaro metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT rahmollerjohann metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT ehlersmarc metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT lehrianselina metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT vonkopylowvera metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT kunstinginga metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT lixenfeldannesophie metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT martinemily metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT ragabmohab metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT meyersaraeiroza metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT kreutzmannfabian metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT eitelingo metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT taubestefan metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT kadingnadja metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT jantzeneckard metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT graftobias metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT sinachristian metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients
AT guntherulrichl metabolicandlipidomicmarkersdifferentiatecovid19fromnonhospitalizedandotherintensivecarepatients